NCT04121455View on ClinicalTrials.gov

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Glioblastoma
Interventions
DRUG

Olaptesed pegol

Olaptesed pegol continuous i.v. administration

RADIATION

Radiotherapy

Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions

DRUG

Bevacizumab

Bevacizumab every 2 weeks i.v. infusion

DRUG

Pembrolizumab

Pembrolizumab every 3 weeks i.v. for 26 weeks

DRUG

Temozolomide (TMZ)

oral treatment according to current SPC

Trial Locations (6)

Unknown

Klinik und Poliklinik für Neurologie Schwerpunkt Klinische Neuroonkologie, Bonn

Klinik für Neurologie, Essen

Klinik für Strahlentherapie und Radioonkologie, Leipzig

Klinik für Strahlentherapie und Radioonkologie, Mannheim

Klinik für Neurologie mit Institut für Translationale Neurologie, Münster

Abteilung Neurologie mit interdisziplinärem Schwerpunkt Neuroonkologie, Tübingen

All Listed Sponsors
lead

TME Pharma AG

INDUSTRY

NCT04121455 - Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | Biotech Hunter | Biotech Hunter